Literature DB >> 20121650

Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes.

Johanna Palmroth1, Proscovia Namujju, Aline Simen-Kapeu, Vesa Kataja, Heljä-Marja Surcel, Marjo Tuppurainen, Merja Yliskoski, Kari Syrjänen, Matti Lehtinen.   

Abstract

The risk of seroconversion for multiple human papillomavirus (HPV) types over time was studied in a cohort of 532 women with cervical HPV infection, prospectively followed-up for >10 y. Of the women who were HPV-antibody positive for at least 1 of the HPV types (6, 11 (low risk, lr), 16, 18, 31, 33, and 45 (high risk, hr)) at baseline, 73-98% seroconverted for 1 or more HPV types over time. Baseline lrHPV-seropositive women had 2.3-fold risk (95% confidence interval (CI) 1.1-4.7) for hrHPV seroconversion, but the opposite was not the case. Cross-protection by the natural HPV16 or HPV18 infection against other types of the HPV species A9 or A7 was not seen. These data suggest that protection against other HPV genotypes (as indicated by the lack of seroconversion) may not be provided by humoral HPV antibodies derived from a natural infection. Instead, these unvaccinated, HPV-antibody-positive women continue to be susceptible to infections by the other HPV genotypes over time.

Entities:  

Mesh:

Year:  2010        PMID: 20121650     DOI: 10.3109/00365540903501608

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  10 in total

1.  Detection of systemic and mucosal HPV-specific IgG and IgA antibodies in adolescent girls one and two years after HPV vaccination.

Authors:  Mirte Scherpenisse; Madelief Mollers; Rutger M Schepp; Chris J L M Meijer; Hester E de Melker; Guy A M Berbers; Fiona R M van der Klis
Journal:  Hum Vaccin Immunother       Date:  2012-11-13       Impact factor: 3.452

2.  A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.

Authors:  Daniel C Beachler; Raphael Viscidi; Elizabeth A Sugar; Howard Minkoff; Howard D Strickler; Ross D Cranston; Dorothy J Wiley; Lisa P Jacobson; Kathleen M Weber; Joseph B Margolick; Susheel Reddy; Maura L Gillison; Gypsyamber D'Souza
Journal:  Sex Transm Dis       Date:  2015-02       Impact factor: 2.830

Review 3.  Clinical trials of human papillomavirus vaccines and beyond.

Authors:  Matti Lehtinen; Joakim Dillner
Journal:  Nat Rev Clin Oncol       Date:  2013-06-04       Impact factor: 66.675

4.  Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses.

Authors:  Mirte Scherpenisse; Rutger M Schepp; Madelief Mollers; Chris J L M Meijer; Guy A M Berbers; Fiona R M van der Klis
Journal:  PLoS One       Date:  2013-09-18       Impact factor: 3.240

5.  Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalence.

Authors:  Proscovia B Namujju; Lea Hedman; Klaus Hedman; Cecily Banura; Edward K Mbidde; Dennison Kizito; Romano N Byaruhanga; Moses Muwanga; Reinhard Kirnbauer; Heljä-Marja Surcel; Matti Lehtinen
Journal:  BMC Res Notes       Date:  2011-06-06

6.  A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.

Authors:  Alberto Monroy-García; Miguel A Gómez-Lim; Benny Weiss-Steider; Georgina Paz-de la Rosa; Jorge Hernández-Montes; Karyna Pérez-Saldaña; Yessica S Tapia-Guerrero; Mariel E Toledo-Guzmán; Edelmiro Santiago-Osorio; Héctor I Sanchez-Peña; María de Lourdes Mora-García
Journal:  Virol J       Date:  2011-02-09       Impact factor: 4.099

Review 7.  Aspects of prophylactic vaccination against cervical cancer and other human papillomavirus-related cancers in developing countries.

Authors:  Kari Natunen; Johannes Lehtinen; Proscovia Namujju; John Sellors; Matti Lehtinen
Journal:  Infect Dis Obstet Gynecol       Date:  2011-07-19

8.  Risk of newly detected infections and cervical abnormalities in women seropositive for naturally acquired human papillomavirus type 16/18 antibodies: analysis of the control arm of PATRICIA.

Authors:  Xavier Castellsagué; Paulo Naud; Song-Nan Chow; Cosette M Wheeler; Maria Julieta V Germar; Matti Lehtinen; Jorma Paavonen; Unnop Jaisamrarn; Suzanne M Garland; Jorge Salmerón; Dan Apter; Henry Kitchener; Julio C Teixeira; S Rachel Skinner; Genara Limson; Anne Szarewski; Barbara Romanowski; Fred Y Aoki; Tino F Schwarz; Willy A J Poppe; F Xavier Bosch; Newton S de Carvalho; Klaus Peters; Wiebren A A Tjalma; Mahboobeh Safaeian; Alice Raillard; Dominique Descamps; Frank Struyf; Gary Dubin; Dominique Rosillon; Laurence Baril
Journal:  J Infect Dis       Date:  2014-03-08       Impact factor: 5.226

9.  Risk of newly detected infections and cervical abnormalities in adult women seropositive or seronegative for naturally acquired HPV-16/18 antibodies.

Authors:  Dominique Rosillon; Laurence Baril; Maria Rowena Del Rosario-Raymundo; Cosette Marie Wheeler; Susan Rachel Skinner; Suzanne Marie Garland; Jorge Salmeron; Eduardo Lazcano-Ponce; Carlos Santiago Vallejos; Tanya Stoney; Bram Ter Harmsel; Timothy Yong Kuei Lim; Swee Chong Quek; Galina Minkina; Shelly Ann McNeil; Celine Bouchard; Kah Leng Fong; Deborah Money; Arunachalam Ilancheran; Alevtina Savicheva; Margaret Cruickshank; Archana Chatterjee; Alison Fiander; Mark Martens; Marie Cecile Bozonnat; Frank Struyf; Gary Dubin; Xavier Castellsagué
Journal:  Cancer Med       Date:  2019-07-05       Impact factor: 4.452

10.  Serum and cervicovaginal IgG immune responses against α7 and α9 HPV in non-vaccinated women at risk for cervical cancer: Implication for catch-up prophylactic HPV vaccination.

Authors:  Ralph-Sydney Mboumba Bouassa; Hélène Péré; Camélia Gubavu; Thierry Prazuck; Mohammad-Ali Jenabian; David Veyer; Jean-François Meye; Antoine Touzé; Laurent Bélec
Journal:  PLoS One       Date:  2020-05-18       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.